|
|
 |
|
Viewing report
|
|
|
|
Current Cardiovascular and Diabetes Blockbusters - Brands at Risk Beware
Datamonitor, April 2002
In 2001, the 100 highest selling global drug brands included 18 CV drugs and five diabetes drugs, which generated sales of $41bn and accounted for 29.2% of the top selling drugs. The sheer size of these markets underlines the vital importance of cardiovascular and diabetes brands to overall market performance and positioning of major pharmaceutical company portfolios. However, competition is fierce, with patents expiring on several key drugs.Draws on the 2002 PharmaVitae brief entitled “The Top 100 Drugs of 2001,” and provides updated sales to H1 2002Looks at the winners and losers of the cardiovascular and diabetes markets and examines factors driving the markets’ highest selling drugsForecasts future trends affecting the sales performance of top-selling products and the resulting impact on their marketing companiesThe battle of leading statins Zocor and Lipitor continues, despite new wars on the horizon - generic competition and new ‘superstatins.’The first ARBs, Cozaar and Diovan, still lead the market although they face a growing threat from new, more efficacious brands with new indications in the pipeline.BMS/Sanofi-Synthelabo’s antiplatelet drug Plavix, launched in 1998, experienced one of the highest growth rates following positive results from the Cure trial. Meanwhile, older products with new indications such as AstraZeneca’s Seloken, and Aventis’ Altace also continue to exhibit strong growth.Access insightful analysis of the most recent dynamics in the cardiovascular and diabetes markets with a view to predicting future trends.Identify the most effective lifecycle management strategies for major brands facing intense competitionBenchmark your marketing and product development strategies against those of leading performers
Customers who bought this item also bought
Future Cardiovascular and Diabetes Blockbusters- Where are they coming from?
Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets
Leading Cardiovascular Players 2002 - Portfolios Requiring Replacement Blockbusters
Diabetes: Targeting Disease Prevention
The Cardiovascular Market Outlook to 2010
Functional Foods, Cardiovascular Disease and Diabetes
The Outlook for Cardiovascular Risk Factors: Epidemiology, market and pipeline analysis
Cardiovascular Disease: Current Research, Devices and Drugs
|
|
|
|
